Day: February 3, 2022

BRENTWOOD, Tenn. and ARLINGTON, Va., Feb. 03, 2022 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (Nasdaq: SGRY) and Privia Health Group, Inc. (Nasdaq: PRVA) today announced a strategic agreement whereby Surgery Partners will leverage the physician enablement capabilities of Privia Health in the state of Montana, and Privia Health will build out a statewide physician provider network that will benefit from Surgery Partners’ high-value surgical capabilities. This agreement marks Privia Health’s entry into the state with Great Falls Clinic, a wholly owned subsidiary of Surgery Partners. Great Falls Clinic, a multi-specialty practice with approximately 65 providers spanning 24 specialties, will serve as the anchor practice for Privia Health as the company extends the single tax ID medical group across the state. The companies have...

Company to release nano emulsified CBN drops to burgeoning sleep aid market COSTA MESA, CA, Feb. 03, 2022 (GLOBE NEWSWIRE) — Sipp Industries, Inc. (OTC Pink: SIPC), a multifaceted corporation specializing in manufacturing, and distribution of commercial and consumer products in the cannabis industry, announces the launch of its first product of the year, Nano CBN Drops (“Nano Drops”), addressing the growing cannabis sleep aid market. Sipp Industries has finalized its formula with the primary ingredient being high-grade nano emulsified CBN (cannabidiol). Similar to CBD, the benefits of CBN include anti-inflammatory, pain relief and enhanced sleep quality.  These drops will be in 100mg and 200mg dosages which can be added sublingually or in any choice of beverage. The CBN drops are completely water-soluble that contribute to the...

Figure 1Harvey Hill Drill ProgramFigure 2Harvey Hill 3D ModelVANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) — Fancamp Exploration Ltd. (“Fancamp” or the “Corporation”) (TSX Venture Exchange: FNC) is pleased announce a 2,000-meter drill program scheduled to take place in March this year on its Harvey Hill exploration project (Figure1). Fancamp and MIRA Geoscience have completed construction of a 3D model of the Harvey Hill project. The 3D model suggests that the mineralized lenses are associated with overturned hinge fold (Figure 2). Drilling will aim at two objectives: potential thickening of the mineralized horizon in the hinge fold and the possibility of extension of the copper mineralization from Harvey Hill towards the Foy Zone situated about 400 metres NW, where copper gold mineralization...

GARDEN CITY, NY, Feb. 03, 2022 (GLOBE NEWSWIRE) — ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present at the MicroCap Rodeo Winter Wonderland Best Ideas Conference, which is being held virtually from February 8 – 11, 2022. Mr. Karkus will deliver his corporate presentation on Wednesday, February 9, 2022 at 12:00 PM ET. Event Webcast URL: https://www.webcaster4.com/Webcast/Page/2840/44555 Mr. Karkus will be available for one-on-one investor meetings on February 10 – 11, 2022.To receive additional information or to schedule a one-on-one meeting, please email angie.wright@issuerdirect.com. About ProPhase Labs ProPhase Labs (Nasdaq: PRPH) (“ProPhase”) is a diversified biotech and genomics company that seeks to leverage its CLIA lab services to...

VIP236 is a first-in-class anticancer agent, optimized using Vincerx’s proprietary modular bioconjugation platform to target aggressive tumors VIP236 demonstrates promising tumor regression in in vivo cancer models and is currently in IND-enabling studies PALO ALTO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced the publication of a peer-reviewed article titled, “A Small Molecule–Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types” in the special issue “The Role of Tumor Microenvironment in Solid Tumors: The New Frontier of Cancer Research” of the journal Cancers. The...

JERSEY, Channel Islands, Feb. 03, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the management team will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. As part of the conference, the Company will be conducting a fireside chat on Thursday, February 17, 2022 at 8:00am ET. BTIG hosted events are intended for prospective and existing BTIG clients only. To request a one-on-one meeting with management or to listen to the live event, please contact your BTIG representative with interest. About Quotient Limited Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics...

MIAMI, Feb. 03, 2022 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) announces that Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has initiated the commercial launch of RAYALDEE® (extended release calcifediol) in Germany, the first launch of RAYALDEE outside the U.S. VFMCRP is OPKO’s commercial partner for RAYALDEE in Europe and selected markets outside the U.S., and the sales kick-off in Germany began with presentations by VFMCRP executives and several nephrology key opinion leaders. RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. VFMCRP has received marketing authorizations for RAYALDEE in 11 European countries and expects to launch in additional markets later this year. “The...

Commitment Towards Eliminating All Current Variable Price Convertible Debt ROSEVILLE, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) — via InvestorWire — InnerScope Hearing Technologies Inc. (OTC: INND) (“InnerScope”), an emerging and disruptive leader in the Direct-to-Consumer Hearing Technology space, today announced that it has successfully negotiated the cancellation of a series of variable price convertible notes, with a total principal amount of $1.1 million held by GS Capital Partners, LLC (“GS Capital”) resulting in a favorable restructuring of its financing agreements. As a result of these transactions, InnerScope has eliminated nearly half of its outstanding variable price convertible notes. The Company anticipates eliminating the remainder of its current variable price convertible notes in several...

FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)   1.        KEY INFORMATION  (a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offereeBlue Prism Group plc(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is advisor and Joint broker to Blue Prism Group plc(d)        Date dealing undertaken:2nd February 2022(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash...